Exploratory Safety Pharmacology: A new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 627-647

  Cavero, Icilio ^a  

^a NONE   (Italy)

Author keywords

Assay validation; Cardiovascular system; CNS; Drug development; Exploratory non clinical development sciences; Exploratory Safety Pharmacology; In silico investigations; Pathways analysis; Regulatory Safety Pharmacology; Respiratory system

Indexed keywords

CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL SOCIETY; PATIENT SAFETY; PHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOPHARMACEUTICS; BIOTRANSFORMATION; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; RESPIRATORY TRACT DISEASES; RISK ASSESSMENT; SAFETY; ZEBRAFISH;

EID: 70449461523     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903362422     Document Type: Review

References (85)

1. ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/LOB/media/ MEDIA504.pdf
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715
3. Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 2008;58:77-87
4. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908
5. Redfern WS, Wakefield ID, Prior H, et al. Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 2002;16:161-173
6. Critical Path Opportunities Report. FDA 2006. Available from: www.fda.gov/oc/ initiatives/criticalpath/reports/opp-report. pdf
7. Bass A, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004;49:145-151
8. ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/LOB/media/ MEDIA2192.pdf
9. Redfern WS, Wakefield ID. Safety pharmacology. In: Jacobson-Kram D, Keller KA, editors, Toxicology testing handbook. Informa Healthcare, NY, London; 2006. p. 33-78
10. Guth BD. Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci 2007;97:4-20
11. Bass AS, Siegl PKS, Gintant GA, et al. Current practices in safety pharmacology. In: Gad SC, editor, Preclinical development. John Wiley & Sons, Inc, NY; 2008.
12. Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. Br J Pharmacol 2008;154:1382-1399
13. ICH Harmonised Tripartite Guideline. E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005). Available from: /www.ich.org/ LOB/ media/MEDIA1476.pdf
14. Cavero I. Safety pharmacology society: 9th Annual Meeting 22-25 September, 2008, Madison, USA. Expert Opinion Drug Saf 2009;8:237-247
15. Guidance for industry safety testing of drug metabolites, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), February 2008Available from: http://www. fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm079266.pdf
16. Lindgren S, Bass AS, Briscoe R, et al. Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008;58:99-109
17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259
18. OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. 2005. Available from: www. oecd.org/dataoecd/55/35/38130292.pdf
19. Valentin JP, Bialecki R, Ewart L, et al. A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009;60:152-158
20. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes Available from: http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do? uri=CELEX:31986L0609:EN:NOT
21. Molecular operating environment. Available from: www. moleculardescriptors.eu
22. OECD. Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models. Available from: www.oecd.org/ dataoecd/55/35/38130292.pdf
23. Aronov AM. Tuning out of hERG. Curr Opin Drug Discov Devel 2008;11:128-140
24. Available from: www.chemcomp.com
25. Tobita M, Nishikawa T, Nagashima R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg Med Chem Lett 2005;15:2886-2890
26. Yap CW, Cai CZ, Xue Y, et al. Prediction of torsade-causing potential of drugs by support vector machine approach. Toxicol Sci 2004;79:170-177
27. Genschow E, Spielmann H, Scholz G, et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 2002;30:151-176
28. Muster W, Breidenbach A, Fischer H, et al. Computational toxicology in drug development. Drug Discov Today 2008;13:303-310
29. Brimecombe JC, Kirsch GE, Brown AM. Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability. J Pharmacol Toxicol Methods 2009;59:29-34
30. Cavero I, Mestre M, Guillon JM, et al. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf 1999;21 (Suppl 1):19-31
31. Whitebread S, Hamon J, Bojanic D, et al. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-1433
32. Redfern WS, Waldron G, Winter MJ, et al. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring? J Pharmacol Toxicol Methods 2008;58:110-117
33. Guth BD, Germeye S, Kolb W, et al. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods 2004,49:159-169
34. Yao X, Anderson DL, Ross SA, et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 2008;154:1446-1456
35. Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC Neurosci 2008;9(Suppl 3):S7
36. Available from: www.genstruct.com
37. Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Lett 2005;579:1872-1877
38. Sivachenko AY, Yuryev A. Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. Expert Opin Ther Targets 2007;11:411-421
39. Mayne JT, Ku WW, Kennedy SP. Informed toxicity assessment in drug discovery: systems-based toxicology. Curr Opin Drug Discov Devel 2006;9:75-83
40. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
41. Interactive Biological Pathways Tool. Available from: www.millipore.com/ pathways/pw/pathways
42. Available from: www.cerep.fr/Cerep/ Users/pages/ProductsServices/ BioPrintServices.asp
43. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2:861-873
44. Azzaoui K, Hamon J, Faller B, et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007;2:874-880
45. Available from: www.biowisdom.com/ content/safety-intelligence-program
46. Meyer T, Sartipy P, Blind F, et al. New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 2007;3:507-517
47. Jensen J, Hyllner J, Björquist P. Human embryonic stem cell technologies and drug discovery. J Cell Physiol 2009;219:513-519
48. Kari G, Rodeck U, Dicker AP. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007;82:70-80
49. Barros TP, Alderton WK, Reynolds HM, et al. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008;154:1400-1413
50. Eimon PM, Rubinstein AL. The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin Drug Metab Toxicol 2009;5:393-401
51. Chakraborty C, Hsu CH, Wen ZH, et al. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr Drug Metab 2009;10:116-124
52. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 2008;9(10):394-401
53. Schierok H, Markert M, Pairet M, et al. Continuous assessment of multiple vital physiological functions in conscious freely moving rats using telemetry and a plethysmography system. J Pharmacol Toxicol Methods 2000;43:211-217
54. Delaunois A, Dedoncker P, Hanon E, et al. Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. J Pharmacol Toxicol Methods 2009;60:117-129
55. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008;154:1528-1537
56. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009;8:317-329
57. Killeen MJ. Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. Drug Discov Today 2009;14:589-597
58. Cavero I, Mestre M, Guillon JM, et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000;1:947-973
59. Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res 1998;39:178-193
60. Lawrence CL, Pollard CE, Hammond TG, et al. Nonclinical proarrhythmia models: predicting torsades de pointes. Pharmacol Toxicol Methods 2006;52:46-59
61. Steidl-Nichols J-V, Hanton G, Leaney L, et al. Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model. J Pharmacol Toxicol Methods 2008;57:9-22
62. Liu T, Brown BS, Wu Y, et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-956
63. Van Deuren B, Van Ammel K, Somers Y, et al. The fentanyl/etomidate- anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. J Pharmacol Toxicol Methods 2009;60:11-23
64. Adeyemi O, Roberts S, Harris J, et al. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation. J Pharmacol Toxicol Methods 2009;60:159-6665.
65. Cavero I. Using pharmacokinetic/ pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 2007;6:465-471
66. Crumb W, Llorca PM, Lancon C, et al. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur J Pharmacol 200;532:270-278
67. Gwathmey JK, Tsaioun K, Hajjar RJ. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin Drug Metab Toxicol 2009;5:647-660
68. Scatena R, Bottoni P, Botta G, et al. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007;293:C12-21
69. Pereira CV, Moreira AC, Pereira SP, et al. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 2009;4:34-54
70. Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009;105(Suppl 1):S14-25
71. Easter A, Bell ME, Damewood JR Jr, et al. Approaches to seizure risk assessment in preclinical drug discovery. Drug Disc Today 2009;14:876-884
72. Guideline on the non-clinical investigation of the dependence potential of medicinal products. Available from: www.emea. europa.eu/pdfs/human/swp/ 9422704en. pdf
73. PhRMA-FDA Dialogue Session. February 20, 2008: PhRMA-FDA dialogue session abuse potential assessments. Available from: www.fda.gov/ cder/offices/CSS/ presentations.htm
74. Herling AW. Gastro intestinal system. Drug discovery and evaluation: safety and pharmacokinetic assays In: HD Vogel, editor, Hock FG, Maas J, Mayer D, co-editors, Springer-Verlag, Berlin, Heidelberg, New York; 2006. p. 152-176
75. Emeigh Hart SG. Safety Pharmacology of drugs for the urinary tract. Drug discovery and evaluation: safety and pharmacokinetic assays In: HD Vogel, editor, Hock FG, Maas J, Mayer, co-editors, Springer-Verlag, Berlin, Heidelberg, New York; 2006. p. 95-140
76. Gedeck P, Lewis RA. Exploiting QSAR models in lead optimization. Curr Opin Drug Discov Devel 2008;11:569-575
77. Dearden JC. In silico prediction of ADMET properties: how far have we come? Expert Opin Drug Metab Toxicol 2007;3:635-639
78. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008;300:1887-1896
79. Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 2008;58:72-76
80. ICH Harmonised Tripartite Guideline. Safety evaluation of biotechnology-derived pharmaceuticals. S6. Available from: www. ich.org/LOB/media/MEDIA503. pdf
81. Bussiere JL, Martin P, Horner M, et al. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 2009;28:230-253
82. Trepakova ES, Koerner J, Pettit SD, et al. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 2009;60:45-50
83. Available from: www.c-path.org/pstc.cfm
84. Valentin JP, Price, S. Overview of the modular training programme in applied toxicology: Module on safety pharmacology in pre-clinical research and development. Br Toxicol Newsletter 2007;30:63-65
85. Bass AS, Cartwright ME, Mahon C, et al. Exploratory drug safety: a discovery strategy to reduce attrition in development. J Pharmacol Toxicol Methods 2009;60:69-78